Three chapters published in June by The United States Pharmacopeial Convention (USP) are under appeal and postponed "until further notice."

Integrating 18FDG-PET/CT radiomic tumor and bone marrow features can help predict outcomes in patients with non-small cell lung cancer, according to a Sept. 17 study published in Radiology.

The Australian Nuclear Science and Technology Organization (ANSTO) confirmed it has shut down its Lucas Heights nuclear medicine facility following a “mechanical fault,” The Guardian reported. The shutdown puts an added strain on Australia’s already short supply of molybdenum-99 (Mo-99).

“We anticipate that these expert multisocietal consensus recommendations on multimodality imaging in cardiac amyloidosis will standardize the diagnosis and improve the management of this highly morbid and underdiagnosed disease," wrote authors of the new guidelines published in the Journal of Nuclear Cardiology.

Using [68Ga]Ga-PSMA-11 PET/CT to monitor treatment response in prostate cancer patients can offer important lesion-based insights over prostate-specific membrane antigen (PSMA)-based monitoring, according to a new study published in EJNMMI Research.

The Department of Energy (DOE)’s National Nuclear Security Administration has issued a fourth, and final, cooperative agreement to Corvallis, Oregon-based Northwest Medical Isotopes, LLC.

In July, SHINE was one of three companies to receive $15 million in funding from the Department of Energy (DOE)’s National Nuclear Security Administration to bolster its production of molybdenum-99 (Mo-99).

The Penn PET Addiction Center of Excellence (PACE) will harness the minds of radiology and psychiatry researchers to better understand opioid use disorder and develop improvement treatment options.

A skin test may help clinicians prevent adverse drug reactions in patients receiving radiocontrast material, according to a new study published in the American Journal of Roentgenology.

The U.S. Nuclear Regulatory Commission (NRC) is asking for comments on its proposed revision to be submitted by Aug. 26.

New research suggests that fluorodeoxyglucose (FDG) PET is better for assessing the severity of Alzheimer’s disease and mild cognitive impairment (MCI) than florbetapir-PET scans.

A recent story in the New York Times analyzed the positives and potential negatives of undergoing an amyloid PET scan to gain insight into one’s risk of developing Alzheimer’s.